Oral and pharyngeal candidiasis

References

• Epstein JB, Truelove EL, Izutzu KT. Oral candidiasis: pathogenesis and host defense. Rev Infect Dis 1984: 6(1): 96–106
   PubMedGoogle Scholar
• Pollock JJ, Denepitiya L, MacKay BJ, et al. Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect Immun 1984: 44(3): 702–7
   PubMed Web of Science ®Google Scholar
• Epstein JB. Kimura LH, Menard TW, et al. Effects of specific antibodies on the interaction between the fungus Candida albicans and human oral mucosa. Arch Oral Biol 1982: 27(6): 469–74
   PubMed Web of Science ®Google Scholar
• Rossie KM, Taylor J, Beck FM, et al. Influence of radiation therapy on oral Candida albicans colonization: a quantitative assessment. Oral Surg Oral Med Oral Pathol 1987: 64(6): 698–701
   PubMedGoogle Scholar
• Dreizen S, McCredie KB, Bodey GP, et al. Quantitative analysis of the oral complications of antileukemia chemotherapy. Oral Surg Oral Med Oral Pathol 1986: 62(6): 650–3
   PubMedGoogle Scholar
• Barrett AP. A long-term prospective clinical study of oral complications during conventional chemotherapy for acute leukemia. Oral Surg Oral Med Oral Pathol 1987: 63(3): 313–6
   PubMedGoogle Scholar
• Dreizen S, Bodey GP, Valdivieso M. Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg Oral Med Oral Pathol 1983: 55(2): 113–20
   PubMedGoogle Scholar
• Silverman S Jr, Migliorati CA, Lozada-Nur F, et al. Oral findings in people with or at high risk for AIDS: a study of 375 homosexual males. J Am Dent Assoc 1986: 112(Feb): 187–92
   PubMed Web of Science ®Google Scholar
• Phelan JA, Saltzman BR, Friedland GH, et al. Oral findings in patients with acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol 1987: 64(1): 50–6
   PubMedGoogle Scholar
• Zunino SJ, Hudig D. Interactions between human natural killer (NK) lymphocytes and yeast cells: human NK cells do not kill Candida albicans, although C. albicans blocks NK lysis of K562 cells. Infect Immun 1988: 56(3): 564–9
   PubMed Web of Science ®Google Scholar
• Lombardi G, Vismara D, Piccolella E, et al. A non-specific inhibitor produced by Candida albicans activated T-cells impairs cell proliferation by inhibiting interleukin 1 production. Clin Exp Immunol 1985: 60(2): 303–10
   PubMed Web of Science ®Google Scholar
• Durandy A, Fischer A, Le Deist F, et al. Mannan-specific and mannan-induced T-cell suppressive activity in patients with chronic mucocutaneous candidiasis. J Clin Immunol 1987: 7(5): 400–10
   PubMed Web of Science ®Google Scholar
• Daniels TE, Schwartz O, Larsen V, et al. Langerhans cells in candidal leukoplakia. J Oral Pathol 1985: 14(9): 733–9
   PubMedGoogle Scholar
• Graybill JR, Craven PC. Antifungal agents used in systemic mycoses: activity and therapeutic use. Drugs 1983: 25(1): 41–62
   PubMed Web of Science ®Google Scholar
• Yang DJ, Rankin GO. Nephrotoxicity of antifungal agents. Adverse Drug React Acute Poisoning Rev 1985: 4(1): 37–47
   PubMedGoogle Scholar
• Rippon JW. A new era In antimycotic agents. (Editorial) Arch Dermatol 1986: 122(Apr): 399–402
   PubMedGoogle Scholar
• Heel RC, Brogden RN, Speight TM, et al. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1978: 16(3): 177–201
   PubMed Web of Science ®Google Scholar
• Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis: a prospective study of 12 cases. Am J Gastroenterol 1983: 78(5): 261–4
   PubMed Web of Science ®Google Scholar
• Jones PG, Kauffman CA, McAuliffe LS, et al. Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 1984: 144(Mar): 549–51
   PubMedGoogle Scholar
• Heel RC, Brogden RN, Carmine A, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982: 23(1–2): 1–36
   PubMed Web of Science ®Google Scholar
• Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983: 74(1B): 80–5
   PubMedGoogle Scholar
• Fardal O, Turnbull RS. A review of the literature on use of Chlorhexidine in dentistry. J Am Dent Assoc 1986: 112(Jun): 863–9
   PubMed Web of Science ®Google Scholar
• Langslet A, Olsen I, Lie SO, et al. Chlorhexidine treatment of oral candidiasis in seriously diseased children. Acta Paediatr Scand 1974: 63(6): 809–11
   PubMed Web of Science ®Google Scholar
• McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a Chlorhexidine mouth rinse regimen. Oral Surg Oral Med Oral Pathol 1985: 60(3): 275–80
   PubMedGoogle Scholar
• Ferretti GA, Ash RC, Brown AT, et al. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 1987: 114(Apr): 461–7
   PubMed Web of Science ®Google Scholar
• DeGregorio MW, Lee WM, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982: 50(12): 2780–4
   PubMed Web of Science ®Google Scholar
• Barrett AB. Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in Immunosuppressed patients. Oral Surg Oral Med Oral Pathol 1984: 58(2): 148–51
   PubMedGoogle Scholar
• Hann IM, Prentice HG, Corringham R, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely Immunocompromised patients. Lancet 1982: 1(8276): 826–9
   PubMed Web of Science ®Google Scholar
• Sharon A, Berdicevsky I, Ben-Aryeh H, et al. The effect of chlorhexidine mouth rinses on oral Candida in a group of leukemic patients. Oral Surg Oral Med Oral Pathol 1977: 44(2): 201–55
   PubMedGoogle Scholar